Background: Nitric oxide (NO), synthesised from the inducible isoform of nitric oxide synthase (iNOS), is implicated in mediating second window of protection (SWOP) / delayed ischemic preconditioning. However the role of NO and iNOS in delayed pharmacological protection remains unclear and is the subject of this investigation. Methods: To test the hypothesis that iNOS is necessary for delayed 6 pharmacological preconditioning, the adenosine A receptor agonist, 2-chloro N cyclopentyl adenosine (CCPA) (25 mg / kg i.v.) or saline 1 was administered to wild type (WT) or iNOS gene knockout mice (KO). Twenty-four hours later, the hearts were isolated, Langendorff perfused and subjected to 35 min ischemia / 30 min reperfusion prior to infarct size determination. Results: WT and KO control hearts had identical infarct sizes of 3763% and 3762%, respectively. CCPA significantly reduced infarct size in WT hearts to 2262% and also, v unexpectedly, in KO hearts (2762%). This protection was abrogated with the non-specific NOS inhibitor, N nitro L-arginine methyl ester (L-NAME, 100 mM), and could be mimicked in naıve hearts with the NO donor, donor S-nitroso N-acetyl DL penicillamine (SNAP, 1 mM). Delayed protection appeared to be mediated by NO synthesis in both WT and KO hearts. Additional studies using Western blot analysis demonstrated endothelial NOS (eNOS) upregulation and increased NO release in both WT and KO hearts. Conclusions: This is x the first study to demonstrate a role for eNOS in delayed A receptor triggered (pharmacological) preconditioning, potentially 1 representing a new pharmacological target for protecting the ischemic heart.
Introduction
ischemia, the mechanisms that trigger and mediate this protection remain unclear. Recent work by Bolli and coPreconditioning results in two temporally distinct phases workers has implicated the synthesis of nitric oxide (NO) of cardioprotection against lethal ischemic injury. The first, as being an important mediator of delayed ischemic known as 'classical preconditioning', has immediate onset preconditioning [3, 4] . Where NO production has been [1], but is of limited duration (2-3 h). The second phase, abrogated, the resistance to lethal ischemia is lost. known as delayed preconditioning or 'second window of NO is synthesised by three isoforms of NO synthase protection' (SWOP), results in cardioprotection 24 h after (NOS) found in myocardium, catalysing the substrate, the preconditioning stimulus, with a duration of 2-3 days L-arginine, to L-citrulline and NO. Endothelial and neuro- [2] .
nal NO synthases (eNOS and nNOS, respectively) are Whilst delayed preconditioning has been shown to be constitutively expressed NOS isoforms whose activity is efficacious in reducing infarct size resulting from lethal regulated by cytosolic concentration of calcium and by the presence of cofactors such as tetra hydrobiopterin (BH ), [6] . Whilst the iNOS protein is detectable at low levels in 2.5 mM) dissected and the aorta cannulated with a 22 unstressed naıve myocardium [4, 7] this observation is of gauge cannula. The hearts were then rapidly transferred to unknown biological significance. However, iNOS is markthe Langendorff apparatus, and perfused retrogradely at edly induced following ischemic stress by signalling constant pressure (110 cmH O). The perfusate was oxy-2 cascades resulting in the upregulation of transcription genated with 95% O / 5% CO gas mixture (perfusate pH 2 2 factors such as NF-kB [8, 9] . This protein transcription 7.4). A temperature probe was inserted into the right leads to upregulation of iNOS and thus NO synthesis has ventricle to enable the maintenance of normothermia led many investigators to hypothesise that iNOS is the (378C) throughout the experiment, and a pacing electrode source of NO in delayed preconditioning. However, recent placed onto the left ventricle. The aortic cannula is work by Vallance et al. in a cytokine model of vascular employed as the earth electrode. Hearts are paced at 600 response to shock in man [10] , has demonstrated that beats / min throughout the stabilisation and for the latter 20 eNOS activity can be markedly upregulated by increased min of reperfusion. BH availability and 'masquerade' as iNOS. The potential Global ischemia was achieved by the cessation of 4 importance of this observation in the context of precondicoronary flow. Normothermia was maintained by submergtioning has not been explored. Furthermore, it remains ing the hearts in warmed (378C) non-oxygenated Krebs unclear whether the mechanisms that mediate delayed Henseleit buffer. Pacing was discontinued after 5 min of pharmacological preconditioning are the same as those ischemia. triggered as a result of delayed ischemic preconditioning.
Contractile function and resting tension were monitored To investigate the comparative importance of the NOS with a linear force transducer (Scame model GM3), with a isoforms in the mediation of delayed pharmacological 3 / 0 silk tie through the apex, recorded on a Gould preconditioning, we used the adenosine A receptor agonWindoGraf chart recorder. ist, 2-chloro N cyclopentyl adenosine (CCPA) as a trigger of delayed preconditioning in both mice with targeted 2.4. Experimental protocols disruption of the iNOS gene and their wild-types.
The study consisted of five groups (summarised in Fig.  1 ). In groups A, B, C and E, WT and KO mice were 2. Methods randomly allocated to i.v. CCPA or control (0.9% saline vehicle) groups. In group C, L-NAME (100 mM) was 2.1. Animals dissolved in the perfusate and present throughout thë ischemia / reperfusion protocol. In group D, naıve WT All experiments were performed on adult female B6,129 hearts were randomly assigned to normal buffer perfusion, mice (3-4 months, 20-25 g). Wild type mice (WT) were or to perfusion with buffer containing 1 mM SNAP. compared to the iNOS knockout (KO) strain, with a targeted mutation of the iNOS gene (Jackson labs: bred 2.5. Determination of infarct size under licence at University College London). Studies were undertaken in accordance with guidelines on the operation TTC staining of hearts have previously been described of the Animals (Scientific Procedures) Act 1986.
[11]. The risk volume is the total ventricular volume, minus the cavity spaces. Infarct size for each heart is 2.2. Drugs and chemicals expressed as a percentage of risk volume.
Constituents for the Krebs Henseleit buffer were purv 2.6. Determination of nitric oxide activity chased from BDH Laboratory supplies. CCPA, N nitro L-arginine methyl ester (L-NAME), S-nitroso N-acetyl Nitric oxide synthase activity in the Langendorff perpenicillamine (SNAP) and triphenyl tetrazolium chloride fused hearts were determined by measurement of the (TTC) were purchased from Sigma Chemical Co.
oxidised products of nitric oxide, nitrite and nitrate (NO ), Mouse heart Langendorff perfusion and protocols have been previously described [11] . In brief, mice anaesthet-2.7. In vivo measurement of blood pressure ised and anticoagulated with 60 mg / kg sodium pentobarbitone i.p. and 100 IU heparin i.p., respectively, underwent
To determine the effect of CCPA upon blood pressure, parasternotomy. The heart and lungs were excised en-bloc arterial pressure lines were inserted into the right common and immersed in ice cold Krebs Henseleit buffer (NaCl carotid artery of halothane anaesthetised, spontaneous 118 mM, NaCO 
Results

Determination of optimal CCPA dose
Whilst adenosine A receptor activation has been dem-1 onstrated to elicit delayed protection against infarction in mammalian species such as rabbit [14] , until recently it was unknown whether A receptor agonists such as 2- 1 6 chloro N cyclopentyl adenosine (CCPA) triggered delayed preconditioning in mice. Therefore, WT hearts were subjected to ischemia / reperfusion as outlined in Fig. 1A , comparing i.v. saline (vehicle), 25 mg / kg and 100 mg / kg CCPA treatment. The mice were observed during and following drug administration, their physical activity noted and recorded. Animals administered with 100 mg / kg CCPA displayed physical evidence of shock (piloerection, haunched posture and minimal provoked behaviour) lasting to vehicle and 25 mg / kg CCPA-treated animals, as indicated in Table 1 . The behaviour of the high dose CCPAtreated mice suggested shock, and to confirm this diagPressures were recorded for 15 min prior to drug injection, nosis, the arterial blood pressure was measured in control, and then for a subsequent 150 min. 25 mg / kg and 100 mg / kg CCPA-treated animals. The results are summarised in Fig. 2B . Both concentrations of CCPA resulted in a significant and rapid drop in mean 2.8. Western blot analysis arterial blood pressure. In the low 25 mg / kg CCPA-treated group, there was rapid blood pressure recovery (at least Hearts of WT and KO mice were harvested 24 h after 80% recovery within 30 min of administration). This vehicle or CCPA as described in Fig. 1E . Total cellular pressure response appears to be equivalent to the pressure protein was extracted and separated by 8% SDS / PAGE trace associated with 100 mg / kg CCPA in rabbit [14] . In (protein loading 60 mg per well) and electrotransferred to contrast however, the higher 100 mg / kg concentration of nitrocellulose membranes (Amersham). eNOS and iNOS CCPA resulted in a markedly and significantly prolonged were detected using rabbit polyclonal antibodies (New depression of blood pressure, requiring up to 2 h to recover England Biolabs) and visualised with an Enhanced Chemia similar level of blood pressure recovery. Luminescence (ECL) detection kit (Amersham). Each NOS Therefore, to avoid systemic hemodynamic depression signal was normalised to the corresponding Ponceau signal (and therefore potential unwanted cytokine induction) or [13] and presented as a proportion of WT control NOS coronary hemodynamic sequelae, the lower 25 mg / kg dose content.
of CCPA was employed for the remainder of this study. detectable. Therefore whilst iNOS may not be pivotal for delayed pharmacological preconditioning, it may be mediated by nitric oxide generated from an upregulated constitutive isoform of NOS.
Nitric oxide -cardioprotective mediator or epiphenomenon?
To determine the importance of nitric oxide synthesis to this form of delayed preconditioning, two approaches were taken: (i) to determine whether attenuation of NO generation abrogated delayed preconditioning and (ii), to investigate whether exogenous NO could mimic preconditioning infarct limitation.
To abrogate all NOS activity during ischemia and reperfusion, a non-specific NOS inhibitor, L-NAME (100 mM) was added to the Krebs Henseleit buffer (protocol, Fig. 1C) . Consistent with the hypothesis that NOS activity is essential for infarct sparing effect of delayed pharmacological preconditioning, L-NAME abrogated CCPA-triggered delayed protection (Fig. 5) .
In the second phase, using naive iNOS KO hearts, the spontaneous NO donor, S-nitroso N-acetyl penicillamine (SNAP, 1 mM) was added to the perfusion buffer (proto- SNAP donates NO with 1:1 stoichiometry at a high rate of degradation; 100 mM SNAP releases 1.4 mM NO / min at 378C, linear over a wide temperature range [15] .
Compared to control hearts perfused with the un-3.2. The role of iNOS in mediating delayed modified Krebs Henseleit buffer, exogenous NO adminispreconditioning tered to iNOS KO hearts reduced infarction to 2161% from 3763% (Fig. 6 ) -equivalent to that observed in Following ischemia and reperfusion, both WT and KO CCPA-treated WT and KO hearts. hearts of animals pretreated with the saline vehicle had equivalent infarct sizes -3763% and 3762%, respectively (Fig. 3) . Prior CCPA administration significantly 3.5. Protein regulation of NOS following CCPA reduced infarct size in WT hearts to 2262% and also, administration unexpectedly, in KO hearts to 2762%, possibly implying that iNOS is not essential for delayed pharmacological The significant synthesis of NO in the iNOS KO group preconditioning.
that is associated with infarct size reduction implies the upregulation of a constitutively expressed NOS isoform.
NOS activity assessment -compensatory NOS
As eNOS isoform is widely expressed in the myocardium upregulation? [16] and eNOS activity appears to be significantly upregulated in the absence of iNOS activity [10], the expression The coronary effluent NO concentrations at the end of of the eNOS and iNOS isoforms were quantified. Conx the 20-min stabilisation period are summarised in Fig. 4 . sistent with the knockout status, no iNOS protein was † Baseline coronary flow was significantly reduced in hearts of animals that had received the higher CCPA dose of 100 mg / kg: P50.003 versus control group and P50.046 versus 25 mg / kg CCPA-treated group. L-NAME resulted in significantly lower coronary flow rates in control WT and KO animals, and in CCPA-treated KO. CCPA-treated WT hearts had a lower mean flow rate, but was not significantly different from the non L-NAME-treated group. † ‡ § P,0.0001 vs. equivalent non-L-NAME group, P50.002 vs. equivalent non-L-NAME group, P,0.004 vs. equivalent non-L-NAME group.
expressed in either vehicle control or CCPA-treated iNOS eNOS content was marginally higher in the control iNOS KO groups (Fig. 7A) . In the iNOS WT group, CCPA KO hearts (138619%) than that found in iNOS WT administration resulted in significant upregulation of iNOS groups (100618%), although the trend was not significant protein content (231617%). Significantly however, CCPA (P50.297). Therefore, delayed pharmacological precondiresulted in upregulation of eNOS content in both iNOS tioning with the adenosine A agonist, CCPA, at a dose of 1 WT and iNOS KO groups (210635% and 241622% of 25 mg / kg, appears to be mediated via the upregulation of iNOS WT control eNOS expression, respectively). ComeNOS and iNOS. Thus in the absence of iNOS the eNOS paring iNOS WT and iNOS KO control animals, baseline may become pivotal to the protection observed. . The effect of L-NAME upon delayed preconditioning with CCPA. L-NAME did not increase infarct size in control hearts when administered Fig. 3 . The effect of delayed pharmacological preconditioning with throughout the perfusion protocol. The NOS inhibitor completely abro-CCPA in both iNOS WT and KO hearts. Infarct size in control iNOS WT gated the protection conferred by prior CCPA administration implicating a and KO hearts were identical. Prior administration of CCPA led to the role for NO in mediating delayed pharmacological preconditioning. attenuation of infarction in WT hearts and unexpectedly in KO hearts. **P,0.001, *P,0.05 versus respective WT and KO vehicle control. Fig. 6 . The effect of the administration of exogenous NO upon infarct size; 1 mM SNAP administered throughout the perfusion protocol leads to significant infarct size limitation equivalent to that observed with delayed preconditioning with CCPA. **P,0.001. The number within the bars signifies the number of animals used. pharmacological delayed preconditioning, we have demon-be mediated via a similar iNOS-dependent mechanism. Adenosine A receptor activation has been shown to 1 trigger delayed preconditioning in a number of animal species including rabbit [14] and rat [21] . In this study, we demonstrate that CCPA administration 24 h prior to a lethal ischemic insult does indeed result in marked reduction of infarction resulting from a lethal ischemic insult in mice, and is consistent with recently published work by Kukreja et al. [22] . However, whereas in species such as rabbit, 100 mg / kg results in a short duration depression of blood pressure [14] , the time course with this concentration in mouse was found to be significantly prolonged. To emulate the short duration hemodynamic changes found in rabbit, 25 mg / kg of CCPA was found to be optimal and still trigger identical protection.
Using the lower 25 mg / kg CCPA dose, we have demonstrated that the delayed protection imbued upon the heart of WT animals is associated with increased NO x release from the heart. This is entirely consistent with the previously proposed 'NO' hypothesis. Remarkably however, iNOS knockout mice (with no demonstrable iNOS protein) display a similar degree of infarct limitation following CCPA administration 24 h earlier. One potential explanation for this observation is that there is a NOindependent signalling mediating protection. However, the NOS activity assay we present here appears to allude to another possibility. In hearts of saline-treated WT and KO mice there was negligible NO release into the coronary triggered protection is attenuated by the non-specific NOS inhibitor, L-NAME, and emulated by the NO donor, SNAP strated that delayed pharmacological preconditioning with in naıve hearts. CCPA appears dependent upon the generation of NO.
If NO is a mediator of delayed CCPA-triggered preHowever, where previous investigations have implicated conditioning in iNOS KO hearts, then a constitutive NOS the inducible isoform of NOS as being the obligatory isoform is responsible for its synthesis: eNOS being the source of NO, our results suggest that another isoform of most likely candidate. Whilst eNOS may have the lowest NOS may have an important role in mediating protection.
intrinsic levels of catalytic activity relative to nNOS and The NO hypothesis for delayed preconditioning as iNOS [6] , it nonetheless has significant capacity to be proposed by Bolli et al. is attractive [17] . A number of upregulated. Several mechanisms exist to augment eNOS recent studies, using pharmacological inhibitors of iNOS activity, which include receptor-mediated translocation [3, 18] or transgenic mice with targeted deletion of iNOS from the sarcolemmal caveoli [23, 24] , eNOS serine 1177 [4, 19] , have implicated the potential of NO in delayed phosphorylation by Akt [25, 26] and cyclic adenosine preconditioning. Moreover, Bolli's group have demonmonophosphate-activated protein kinase [27, 28] , and strated that transient ischemia results in protein kinase C HSP90 interaction with eNOS [29, 30] . The potential for (PKC) activation and translocation [20] , activation of the eNOS activity to be significantly increased following a transcription factor NF-kB and ultimately iNOS induction stressful stimulus has been demonstrated by Bhagat et al. and expression [8] , providing further support for the in a human vascular model of cytokine-triggered septic hypothesis.
shock [10] . They demonstrated that eNOS was capable of With this evidence in mind, we anticipated that pharmagenerating significant quantities of NO through the induccologically triggered delayed preconditioning would also tion of GTP cyclohydrolase-1 expression and activity and thus increasing the bioavailability of the co-factor, tetra protection against infarction may be of clinical importance, hydrobiopterin (BH ). Therefore it appears to be feasible as well as providing a potential target for future drug 4 for eNOS to emulate iNOS under certain circumstances. It development. is therefore attractive to postulate that the data presented here is an example of eNOS 'masquerading' as iNOS in delayed pharmacological preconditioning. This hypothesis Acknowledgements appears to be supported by Western blot analysis of the protein content of hearts 24 h following CCPA administraThis work was supported by a grant from the British tion. Whilst there is a clear increase in iNOS protein over Heart Foundation. We would like to thank Valerie Taylor basal expression in hearts of WT CCPA-treated mice, no from Patrick Vallence's Laboratory for her technical iNOS protein was found in either of the iNOS KO groups.
assistance in the measurement of in-vivo blood pressure Interestingly, in both WT and KO hearts, there was also a monitoring. marked and significant increase of eNOS protein content. Thus there appears to be evidence to support the hypothesis that eNOS does have a role to play in the mediation of References delayed pharmacological protection.
The present study appears to contradict three recent using ischemia to precondition the myocardium, Bolli et al.
[2] Baxter GF, Yellon DM. protocol was performed in-vitro 24 h after the i.p. drug observed difference between these studies and the data the studies where we have used female mice. However,
